Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sonpavde

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Postgraduate Medicine|May 1, 1999
What to do when you discover testicular cancer. Helping patients overcome fear and choose treatmentG Sonpavde, L H Einhorn
British Journal of Cancer|September 6, 2012
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinomaG Sonpavde, T K Choueiri
Cancer Research|April 15, 2000
Antileukemic activity of Flt3 ligand in murine leukemiaA Wang, S E Braun, G Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2014
New agents for prostate cancerN Agarwal, G Di Lorenzo, G Sonpavde, et al.
British Journal of Cancer|October 29, 2014
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitorsP Ghatalia, Y Je, M D Kaymakcalan, et al.
Prostate Cancer and Prostatic Diseases|September 28, 2016
Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancerG Sonpavde, G R Pond, A J Templeton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2013
Penile cancer: current therapy and future directionsG Sonpavde, L C Pagliaro, C Buonerba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysisD Raggi, R Miceli, G Sonpavde, et al.
American Journal of Clinical Oncology|February 22, 2000
Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group TrialG Sonpavde, R Ansari, P Walker, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|October 14, 2010
Tissue-based molecular markers for bladder cancerC E Barbieri, Y Lotan, R K Lee, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Postgraduate Medicine|May 1, 1999
What to do when you discover testicular cancer. Helping patients overcome fear and choose treatmentG Sonpavde, L H Einhorn
British Journal of Cancer|September 6, 2012
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinomaG Sonpavde, T K Choueiri
Cancer Research|April 15, 2000
Antileukemic activity of Flt3 ligand in murine leukemiaA Wang, S E Braun, G Sonpavde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2014
New agents for prostate cancerN Agarwal, G Di Lorenzo, G Sonpavde, et al.
British Journal of Cancer|October 29, 2014
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitorsP Ghatalia, Y Je, M D Kaymakcalan, et al.
Prostate Cancer and Prostatic Diseases|September 28, 2016
Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancerG Sonpavde, G R Pond, A J Templeton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2013
Penile cancer: current therapy and future directionsG Sonpavde, L C Pagliaro, C Buonerba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysisD Raggi, R Miceli, G Sonpavde, et al.
American Journal of Clinical Oncology|February 22, 2000
Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group TrialG Sonpavde, R Ansari, P Walker, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|October 14, 2010
Tissue-based molecular markers for bladder cancerC E Barbieri, Y Lotan, R K Lee, et al.
Pageof 3